Drug Patent Holder Disclaimed Infringement Argument, Federal Circuit Says
WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel affirmed a Delaware federal judge’s findings after a bench trial that a generic drug maker’s abbreviated new drug application (ANDA)...To view the full article, register now.
Already a subscriber? Click here to view full article